Press release -
Developed a highly sensitive measurement system for diagnosis of high-risk prostate cancer. Enabling highly effective and rapid detection of cancer while reducing the burden on patients -- Kindai University
A research team led by Associate Professor Kazutoshi Fujita of Kindai University (Osakasayama City, Osaka) Faculty of Medicine (Department of Urology) developed, through collaborative study with Osaka University Graduate School of Medicine (Suita City, Osaka), a new diagnostic method for high-risk prostate cancer using a measurement system for "serum core-type fucosylated PSA"*1, tumor marker produced by epithelial cells of prostate gland. The result of this research allows for highly sensitive measurement and reduction of time required for a single test from 60 minutes to 9 minutes, enabling efficient cancer detection without unnecessary biopsy.
This research was published online in the "International Journal of Cancer", a medical journal primarily publishing clinical researches, on Thursday, February 18th, 2021 (Japan time).
- Measures serum core-type fucosylated PSA, which was not possible in the past, with high speed and high sensitivity
- Verified that fucosylated PSA index*2 significantly rises in a man with high-risk prostate cancer
- Adjunct in the conventional PSA test, high-risk prostate cancer can be effectively detected
International Journal of Cancer (Impact factor: 5.145 @ 2019)
Research paper title:
Serum core-type fucosylated PSA index for the detection of high-risk prostate cancer
Kazutoshi Fujita1,2, Koji Hatano2, Eisuke Tomiyama2, Yujiro Hayashi2, Makoto Matsushita2, Mutsumi Tsuchiya2, Tomoyasu Yoshikawa3, Mutshuhiro Date3, Eiji Miyoshi4, and Norio Nonomura2
1 Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan
2 Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
3 Fujifilm-Wako Inc., Osaka, Japan
4 Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Japan
*1 Serum core-type fucosylated prostate-specific antigen (PSA)
Prostate-specific antigen (PSA) is produced by cancer cells, as well as normal cells, of prostate gland. The level of PSA in blood increases in a man with prostate cancer, but other conditions such as benign prostatic hyperplasia and prostatitis may also increase the PSA level. Serum PSA by conventional measurement is not associated with grade of malignancy.
Protein bound PSA and free PSA exist in blood; when a glycosylation site of free PSA is core-type fucosylated, it is called core-type fucosylated free PSA.
*2 Fucosylated PSA index
FPI is calculated by dividing the serum PSA level by the percentage of non-fucosylated free PSA.